Compare Amphastar Pharmaceuticals Inc (AMPH) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while SYSCO Corporation trades at $84.25 (market cap $40.14B). The key difference: SYSCO Corporation is far larger — about 46.5× Amphastar Pharmaceuticals Inc's market cap, and SYSCO Corporation pays a 2.62% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SYY | |
|---|---|---|
Market Cap | $863.95M | $40.14B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $91.16 |
52-Week Low | $16.87 | $69.30 |
Enterprise Value | $1.26B | $53.32B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Sysco (SYY) trades at $84.29, showing minimal daily movement (-0.07%) amid bullish technical signals and strong institutional support. The company delivered solid Q4 2026 results with EPS of $1.53 beating estimates, supported by 4.7% revenue growth and improved operational efficiency. With a P/E of 23.03 and ROE of 78.16%, fundamentals remain robust despite modest net margins of 2.08%. Recent news highlights supply chain initiatives and steady customer demand driving positive outlook.
Outlook remains positive with analyst consensus target of $88.25 (4.7% upside) and 60% buy ratings. Key opportunities include continued market share gains and cost efficiency benefits, while risks involve margin pressure from inflation and competitive food distribution landscape. The stock presents a balanced growth opportunity with defensive characteristics in foodservice distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
